The title of the most prevalent gynecologic cancer in the United States is held by endometrial cancer (EC). The target of this study was to describe the clinical and pathologic characteristics that are related to endometrial cancer-specific death for women who were being taken care of at a single National Cancer Institute-designated comprehensive cancer center.

This is a backdated cohort from 2014 to 2017 which takes account of all women who had a hysterectomy for EC. Charts were studied, mainly focusing on survival outcomes, in order to gather clinical and pathological information.


Out of the 771 patients diagnosed with EC that underwent a hysterectomy, 760 were found educational for results. The deaths of 76 (10%) patients were related to their endometrial cancer; 62 women passed away due to the reappearance of their EC. Nonendometrioid histology and progressed stage were indicators of repetition and EC demise. Amidst the patients with endometrioid ECs, mismatch repair (MMR) status was essentially connected with EC-specific survival (relative risk = 4.8; 95% confidence interval, 2.3–10.3; p < .0001). Most of the patients whose EC recurred died of their illness 62/83 (74.7%). Almost 50% of those who had recurring EC (27/62) had no extra treatment during the time the disease resurfaced. Women who received extra treatment during the time of the recurrence had an essentially longer overall survival. However, the effects in those women who were adjuvant therapy-naive were a huge factor in the improvement in overall survival with therapy at the repetition of the EC.

Roughly only 50% of patients had the opportunity to get treatment even though there is an advantage of treatment at the time of repetition for treatment-naive females. There is a dire requirement for carrying out these endeavors for more successful EC treatment in both the front-line and recurrent setting as well as early recognition of cancer diagnosis and recurrence.